Comparison Between Effect of Glimepiride and Pioglitazone on the C-Reactive Protein Level of Type 2 Diabetic Patient

Authors

  • AKM Fazlul Haque Medical Officer, Asthma Centre, NIDCH, Mohakhali, Dhaka
  • Md Zahirul Haque Assistant Professor of Medicine, Rajshahi Medical College
  • ARM Saifuddin Ekram Professor of Medicine, Rajshahi Medical College
  • M Azizul Hoque Associate Professor of Medicine, Rajshahi Medical College
  • Quazi Tarikul Islam Professor of Medicine, Dhaka Medical College

DOI:

https://doi.org/10.3329/jom.v12i1.6929

Keywords:

Type-2 diabetes, hs-CRP, Glimepiride, Pioglitazone, Cardiovascular complication

Abstract

Background: This study was carried out to see the effect of glimepiride and pioglitazone on the serum hs-CRP level in type 2 diabetic patients.

Material and Methods: A non-blind comparative study was conducted among 70 patients with type 2 diabetes (as per WHO criteria) divided into two groups (35 each) to see the effect of glimepiride and pioglitazone on their blood hs-CRP level.

Results: 35 type-2 diabetic patients were given glimepiride. Another 35 patients were given pioglitazone. Fasting blood sugar, HbA1c%, hs-CRP and lipid profile were estimated before and 12 weeks after intervention. The mean change of serum hs-CRP was 1.13 mg/L to 0.76 mg/L in pioglitazone group. In glimepiride group the mean change of serum hs-CRP was 0.96 mg/L to 0.94 mg/L after 12 weeks. The change was greater in pioglitazone group in comparison to glimepiride group.

Conclusion: Reduction of hs-CRP was significant in the study subjects revealing its future potential in reducing the vascular complications of type - 2 diabetes mellitus.

Keyword: Type-2 diabetes; hs-CRP; Glimepiride; Pioglitazone; Cardiovascular complication

DOI: 10.3329/jom.v12i1.6929

J Medicine 2011; 12 : 30-33

Downloads

Download data is not yet available.
Abstract
93
PDF
61

Downloads

How to Cite

Haque, A. F., Haque, M. Z., Ekram, A. S., Hoque, M. A., & Islam, Q. T. (2011). Comparison Between Effect of Glimepiride and Pioglitazone on the C-Reactive Protein Level of Type 2 Diabetic Patient. Journal of Medicine, 12(1), 30–33. https://doi.org/10.3329/jom.v12i1.6929

Issue

Vol. 12 No. 1 (2011)

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).